We have established a simple, sensitive and reproducible sandwich enzyme-linked immunosorbent assay (ELISA) for quantitation of immunoglobulins of λ VI subgroup (Ig λ VI) which has been of special interest by its amyloidogenicity. It used murine monoclonal antibodies specific for λ VI subgroup of variable region (V
L) and for λ type of constant region (C
L) of human immunoglobulin light chains. The λ VI protein level and the percent distribution of λ VI subgroup among total Igλ proteins (λ VI/λ ratio) in serum were determined. Igλ VI proteins were contained in each of serum specimens tested. In serum specimens obtained from 44 normal subjects and 14 patients with polyclonal hypergammaglobulinemia and six patients with hypogammaglobulinemia, the concentration (mean±SD) of Igλ VI proteins was 78 to 432 (197±81), 218 to 1875 (648±474) and 49 to 115 (85±25) μg/m
l and that of total Igλ proteins was 2, 640 to 8, 300 (4, 712±1, 454), 8, 197 to 30, 000 (14, 837±7, 029) and 890 to 1, 800 (1312±340) μg/m
l, and the λ VI/λ ratio (mean±SD) was 1.2 to 9.4 (4.3±1.7), 2.1 to 6.4 (4.2±1.7) and 4.6 to 9.2 (6.5±1.6)%, respectively. The λ VI/λ ratio was strikingly higher than 10% in serum specimens from three patients with λ VI-related amyloidosis, which implied clinical and diagnostic availability of this ratio. In patients with rheumatoid arthritis, systemic lupus erythematosus and liver cirrhosis presenting polyclonal hypergammaglobulinemia, λ VI proteins were contained at high concentration in serum, but no amyloid deposition was found in biopsied specimens. However, further study on more cases with polyclonal Igλ VI protein overproduction is required to elucidate amyloidogenicity of non-malignant Igλ VI proteins. The assays described here will facilitate the study on monoclonal and polyclonal nature of this unique λ VI subgroup in various disease conditions.
View full abstract